CortagenvsSemax

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide belonging to the Khavinson family of peptide bioregulators — short peptides proposed to regulate gene expression in a tissue-specific manner. The bioregulator hypothesis, developed by Professor Vladimir Khavinson over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides (2-4 amino acids) can penetrate cell membranes and nuclear envelopes, interact directly with DNA in a sequence-specific manner, and modulate transcription of tissue-relevant genes.

Cortagen is specifically designed to target neurons of the cerebral cortex. According to the Khavinson model, the AEDP tetrapeptide sequence has complementarity to specific DNA sequences in gene promoter regions active in cortical neurons. Upon binding to these regulatory elements, Cortagen is proposed to modulate chromatin structure and transcription factor access, influencing the expression of genes involved in neuronal function, synaptic transmission, antioxidant defense, and protein synthesis. The tissue specificity — cortex rather than other brain regions or body tissues — is attributed to the unique chromatin accessibility and transcription factor environment in cortical neurons that determines which genes are available for regulation.

Preclinical studies from Russian research programs have reported that Cortagen treatment improves cognitive function, enhances learning and memory, and provides neuroprotection in models of cerebral ischemia and age-related cognitive decline. The proposed mechanism involves restoration of age-related declines in protein synthesis in cortical neurons, enhancement of antioxidant enzyme expression (SOD, catalase, GPx), and improved synaptic function through upregulation of synaptophysin and other synaptic proteins. It should be noted that the peptide bioregulator field remains controversial in Western pharmacology — while the Russian research program is extensive, the proposed direct DNA-binding mechanism has not been independently validated through the standard molecular biology methods expected in Western peer-reviewed literature.

Semax is a synthetic heptapeptide consisting of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) — the shortest sequence of ACTH that retains neurotrophic activity — with a Pro-Gly-Pro C-terminal extension for proteolytic stability. Crucially, it contains only the neurotrophic portion of ACTH without the N-terminal amino acids (residues 1-3) required for adrenal cortex stimulation, so it has no effect on cortisol production or the HPA stress axis.

Semax's primary nootropic mechanism is upregulation of neurotrophic factors in the hippocampus and cortex. It increases expression of brain-derived neurotrophic factor (BDNF) — the most important neurotrophin for learning and memory — through activation of the TrkB receptor signaling cascade (Ras/MAPK and PI3K/Akt pathways). BDNF promotes dendritic spine formation, enhances long-term potentiation (the cellular basis of memory), and supports neuronal survival. Semax also upregulates nerve growth factor (NGF), which maintains cholinergic neurons in the basal forebrain — the same neurons that degenerate in Alzheimer's disease and are critical for attention and memory.

At the neurotransmitter level, Semax modulates three monoamine systems. It enhances dopaminergic transmission in the prefrontal cortex and striatum, improving motivation, reward processing, and executive function. It modulates serotonergic activity (5-HT) in the raphe nuclei and limbic system, affecting mood and emotional regulation. It also enhances noradrenergic signaling from the locus coeruleus, improving alertness, focused attention, and working memory. The noradrenergic effect may be particularly relevant for its clinical use in ADHD-like conditions and attention disorders. In stroke recovery (an approved indication in Russia), Semax provides neuroprotection through multiple mechanisms: BDNF-mediated anti-apoptotic signaling, reduction of glutamate excitotoxicity, decreased oxidative stress, and maintenance of blood-brain barrier integrity in the peri-infarct region.